TrumpRX Expands Sevenfold with Mark Cuban Partnership to Cut Prescription Drug Costs

President Donald Trump announced a major expansion of the TrumpRX initiative, increasing the number of available drugs nearly seven times by adding 600 affordable generic medications to the platform in partnership with industry leaders, including Mark Cuban’s drug company.

In the announcement, Trump highlighted that cost-effective generic drugs are often available at a tiny fraction of the price of brand-name equivalents while being essentially the same. He described the move as shifting from healthcare experiments to genuine market disruption.

Mark Cuban, who had been an outspoken critic of Trump and supported Kamala Harris in the 2024 election, has joined the effort. Trump noted that Cuban was “very gracious” and wanted to be part of the initiative.

“That was last season,” Cuban reportedly said, emphasizing that ideology goes out the window when results matter. “The goal is the goal. I love people. Love our country. A good company. He will do a lot of business with us. This is something that really works.”

Trump expressed respect for Cuban, stating he has “a lot of respect for Mark, frankly, and I always have.”

Business commentator Charlie Gasparino, appearing on the panel, described the partnership as a win-win for Cuban’s business, noting that the government would be directing people toward the website. Gasparino observed that the two men have known each other for years and suggested Cuban may regret the intensity of his previous political involvement.

“I kind of think they like each other aside from the political rhetoric,” Gasparino said. He added that politics has given way to practical business outcomes in this case.

The panel discussed the broader context of the initiative. Gasparino noted that while the expansion provides cheaper access to generics — which make up about 90% of prescriptions — and could generate significant savings, it addresses only part of the structural problems in healthcare. He stressed the need for greater access to experimental treatments, particularly for serious conditions like cancer.

He referenced a Wall Street Journal story about a woman who died of brain cancer that developed from melanoma during pregnancy, highlighting difficulties in obtaining experimental treatments not yet approved by the FDA.

Panelists acknowledged that the TrumpRX approach focuses on generics and negotiated lower prices rather than discounts alone, aiming to level the playing field with other countries that benefit from lower negotiated prices while Americans have historically paid more. Trump has pressured drugmakers and foreign nations to ensure fairer contributions.

Gasparino called the effort “a smart play by the President to really bring down drug costs” and a “good step in the right direction,” though he cautioned it would not fully resolve runaway healthcare costs or impact high-margin areas like new cancer drugs or GLP-1 medications.

The discussion reinforced that politics should not obstruct improvements in drug pricing that benefit Americans’ health and the broader economy.